Q-omics provides the consensus-scored TEKT4P3 profile across patient tissues and cancer cell-line models. TEKT4P3 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TEKT4P3 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, TEKT4P3 RNA expression shows 6,549 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight COAD, and BRCA as cancer lineages where TEKT4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEKT4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEKT4P3 survival associations across molecular data types. TEKT4P3 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEKT4P3 RNA expression–survival associations across cancer types. High TEKT4P3 expression shows unfavorable associations in COAD, KICH, MESO, CESC, LGG and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TEKT4P3 RNA expression.
This table summarizes TEKT4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TEKT4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEKT4P3 shows higher tumor expression in BRCA. The BRCA box plot shows higher TEKT4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .014).
This table shows molecular features associated with TEKT4P3 in patient tissues and cancer cell lines. In patient samples, TEKT4P3 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
